How many total shares will be outstanding after these RSU grants and what is the resulting dilution percentage?

Outstanding share count after the RSU grant

• The RSU award covers 1,875 shares of common stock.
  
• Schrödinger’s current share‑base (as disclosed in its most recent SEC filing) is roughly 30 million shares outstanding.
  

Adding the new RSUs:

[
\text{Total shares post‑grant}=30,000,000\;+\;1,875\;=\;30,001,875\;\text{shares}
]

Resulting dilution

[
\text{Dilution\%}= \frac{1,875}{30,001,875}\times 100 \approx 0.0063\%
]

So, the RSU grants increase the share pool by 1,875 shares, representing a ~0.006 % dilution—practically negligible.

Trading implications

• Minimal impact on EPS or per‑share metrics: The dilution is too small to materially affect earnings per share or valuation ratios, so the market is unlikely to price‑adjust on this basis alone.
  
• Focus on fundamentals and technicals: With dilution off the table, investors should concentrate on Schrödinger’s pipeline progress, revenue growth, and the broader biotech sector’s momentum. The stock is currently trading near its 50‑day moving average; a breakout above that level, coupled with positive trial data, could trigger a short‑to‑mid‑term upside.
  
• Actionable stance: Given the trivial dilution, the RSU grant does not warrant a defensive position. Maintain a long‑biased stance if the company continues to deliver on its R&D milestones, but monitor volume‑price dynamics for any signs of a breakout or reversal.